文献速递骨软组织肉瘤与黑色素瘤

挪威2008-2022年I-III期黑色素瘤复发风险

Risk of recurrence of stage I to III melanoma in Norway, 2008-2022.
PubMed 文献 · Eur J Cancer · 2026-07-10

这项全国性队列研究纳入2008-2021年挪威癌症登记处记录的24,095例首次原发性I-III期黑色素瘤患者,随访至复发、无复发生存死亡或诊断后10年。10年累积复发风险为16.7%,无复发死亡风险为17.8%,复发风险在诊断后前3年快速上升。

要点

  • 10年累积复发风险16.7%,1年5.8%,3年11.1%
  • III期患者10年复发风险最高达47.8%
  • 肿瘤厚度>4.00mm者10年复发风险43.4%

核心结论

  • 首次原发性I-III期黑色素瘤诊断后10年累积复发风险为16.7%,无复发死亡风险为17.8%。

研究设计与样本

  • 全国性队列研究纳入2008-2021年挪威癌症登记处记录的24,095例年龄≥18岁首次原发性I-III期黑色素瘤患者。

主要发现

  • 24,095例患者中3,276例复发,2,844例无复发死亡。
  • 累积复发风险从1年5.8%(95%CI 5.5-6.1%)升至3年11.1%(95%CI 10.6-11.5%),10年达16.7%(95%CI 16.2-17.3%)。
  • 10年复发风险最高见于男性20.6%、70-79岁患者20.8%、TNM III期47.8%、肿瘤厚度>4.00mm者43.4%、溃疡型37.0%、结节型31.5%、头颈部21.7%。

临床怎么用

  • 研究结果可为风险分层随访策略提供实证依据,尤其应关注诊断后早期随访阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary population-based data on patterns of melanoma recurrence remain limited, yet are required for planning treatment and surveillance. We aimed to estimate the risk of recurrence following a first primary invasive melanoma, by time since diagnosis, and by patient and tumour characteristics. METHODS: This nationwide cohort study included patients aged ≥ 18 years with a first primary melanoma, stage I-III (American Joint Committee on Cancer, 8th Edition), recorded by the Cancer Registry of Norway in 2008-2021. Patients were followed-up until the first melanoma recurrence, death (without recurrence), or 10 years post-diagnosis, whichever occurred first. Study outcomes were cumulative risk, overall and by patient and tumour characteristics, were estimated using the Aalen-Johansen estimator. RESULTS: Among 24,095 included patients, 3276 experienced a recurrence, while 2844 died without recurrence. The cumulative recurrence risk increased rapidly from 5.8% (95% confidence interval, (CI): 5.5-6.1%) at 1 year to 11.1% (CI: 10.6-11.5%) at 3 years and then rose more gradually to a 10-year recurrence risk of 16.7% (CI: 16.2-17.3%). Death without recurrence increased steadily throughout follow-up. The highest 10-year recurrence risks were observed in men (20.6%), patients aged 70-79 (20.8%), TNM stage III (47.8%) and those with tumours > 4.00 mm thick (43.4%), or melanomas that were ulcerated (37.0%), nodular (31.5%), or on the head/neck (21.7%). CONCLUSIONS: 10-year recurrence risk after diagnosis of a first primary melanoma was 16.7%, compared with 17.8% risk of death without recurrence. These findings provide an empirical basis for risk-stratified surveillance strategies, particularly during the early follow-up period.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Giorcelli A, Valberg M, Green AC, et al. Risk of recurrence of stage I to III melanoma in Norway, 2008-2022. Eur J Cancer. 2026. PMID: 42475979. doi:10.1016/j.ejca.2026.116940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。